Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer letters

Showing results (181-190 of 17,056) with videos related to

Pageof 1,706
Sort By:
Cancer Letters|July 13, 2014
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapyJanet M Pavese, Raymond C Bergan
Cancer Letters|July 13, 2014
Targeted biopharmaceuticals for cancer treatmentLufang Zhou, Ningning Xu, Yan Sun, et al.
Cancer Letters|September 7, 2014
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityOliver Ou, Konrad Huppi, Sirisha Chakka, et al.
Cancer Letters|September 15, 1989
Studies on the kinetics of expression of cell cycle dependent proto-oncogenes during mitogen-induced liver cell proliferationP Coni, F A Bignone, G Pichiri, et al.
Cancer Letters|September 15, 1989
Modulation by some natural carotenoids of DNA adduct formation by aflatoxin B1 in vitroU C Goswami, T N Saloi, P F Firozi, et al.
Cancer Letters|April 10, 2016
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)Jeng-Wei Lu, An-Ni Wang, Heng-An Liao, et al.
Cancer Letters|April 10, 2016
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repairDiana H Liang, Dong Soon Choi, Joe E Ensor, et al.
Cancer Letters|March 16, 2016
Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancerXiaoyu Qin, Xinxin Wang, Feng Liu, et al.
Cancer Letters|March 11, 2016
Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancerPeng Zou, Yiqun Xia, Jiansong Ji, et al.
Cancer Letters|March 12, 2016
High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancerGaëlle Judes, Khaldoun Rifaï, Marine Daures, et al.
Pageof 1,706

Showing results (181-190 of 17,056) with videos related to

Sort By:
Pageof 1,706
Cancer Letters|July 13, 2014
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapyJanet M Pavese, Raymond C Bergan
Cancer Letters|July 13, 2014
Targeted biopharmaceuticals for cancer treatmentLufang Zhou, Ningning Xu, Yan Sun, et al.
Cancer Letters|September 7, 2014
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityOliver Ou, Konrad Huppi, Sirisha Chakka, et al.
Cancer Letters|September 15, 1989
Studies on the kinetics of expression of cell cycle dependent proto-oncogenes during mitogen-induced liver cell proliferationP Coni, F A Bignone, G Pichiri, et al.
Cancer Letters|September 15, 1989
Modulation by some natural carotenoids of DNA adduct formation by aflatoxin B1 in vitroU C Goswami, T N Saloi, P F Firozi, et al.
Cancer Letters|April 10, 2016
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)Jeng-Wei Lu, An-Ni Wang, Heng-An Liao, et al.
Cancer Letters|April 10, 2016
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repairDiana H Liang, Dong Soon Choi, Joe E Ensor, et al.
Cancer Letters|March 16, 2016
Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancerXiaoyu Qin, Xinxin Wang, Feng Liu, et al.
Cancer Letters|March 11, 2016
Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancerPeng Zou, Yiqun Xia, Jiansong Ji, et al.
Cancer Letters|March 12, 2016
High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancerGaëlle Judes, Khaldoun Rifaï, Marine Daures, et al.
Pageof 1,706